

An Alternative Arm Restraint Systems Improves the Lives of ICU Patients

March 9, 2023

Patients who are in intensive care units (ICU) or require critical care are often sedated and restrained to prevent them from removing vital support lines or harming themselves. But sedating and restraining patients can also lead to complications during their stays and after they return home, such as muscle weakness, balance problems, cardiopulmonary issues, cognitive decline, delirium, anxiety, depression, and nightmares. Dr. Marie Pavini, an ICU physician with more than 20 years of experience, was committed to developing an alternative arm restraint system to address these challenges. "There are 27,000 adults in the ICU every day that are restrained," said Pavini, "There definitely is another way, we just needed another tool."

In 2016, Pavini founded Healthy Design, a Vermont-based company, and manufactured the first prototype of the Exersides Refraint System. Instead of restraining patients by tying them to bed, the Exersides Refraint System uses auto-adjusting wrist straps and a loosely applied strap to allow patients to maintain arm movement. The 3.5-pound system also contains and deflects vital tubes and lines, preventing patients from getting entangled in or removing them.

According to a pilot study conducted in 2017, patients using the Exersides Refraint System had more in-bed movement, less sedation, and less agitation compared to patients using traditional arm restraint systems. In addition, patients, families, and nurses involved in the pilot study preferred this system. Along with these benefits, the system is latex-free, MRI-compatible, and easily adjustable so health care providers can adjust the range of motion to best fit the patient's predicted range of safe arm movement.

Healthy Design received funding through the NIH SBIR and STTR programs to assist with the development, testing, and commercialization of the Exersides Refraint System.

77





Healthy Design/HDmedical

13 Willow Street Rutland, VT 05701-4010

State-District

Technology

Medical Device

Primary Institute N/A

Project Details from NIH RePORTER Healthy Design

Contact

Dr. Marie Pavini, President hello@hdmedical.org

https://www.hdmedical.org/

EXERSIDES°



(continued on back)



Healthy Design received funding through the NIH Small Business Technology Transfer (STTR) and Small Business Innovation Research (SBIR) programs to assist with the development, testing, and commercialization of the Exersides Refraint System. Specifically, the company received a STTR grant in 2018 to optimize and test the system in older, critically ill, mechanically ventilated patients. The aim of the project was to reduce immobility, sedation, agitation, and cognitive impairment. "Each NIH grant allows you to add more features and refine the system to the perfect version that it is now," said Pavini.

After successful Phase I and Phase II tests, Healthy Design received additional SBIR funding in 2021 to commercialize, manufacture, and market the Exersides Refraint System. Now the system is available for patients both nationally and internationally.

"I've been accepted into their commercialization accelerator program, which I completed recently. I was also asked to present at two different investor partner conferences that led to other awards and other invitations," said Pavini. "It's just incredible that the NIH has been there to help me. None of this would have happened without that."

Clinical Trials

A Novel Physical Restraint Alternative for Early Mobilization, Delirium Prevention and Sedation Minimization in Intubated Patients.

Pavini, Marie MD; Washburn, Jolana RN. Department of Critical Care, Rutland Regional Med Ctr, Rutland, VT, US. 2017.

RESULTS

Less sedation; Better agitation scores; More movement; Better interaction

Better Patient satisfaction, Better Family satisfaction, Better Staff satisfaction

n=10	Pre-study propofol (mcg/kg/hr)	During study propofol (mcg/kg/hr)	SAS*	Time spent moving (hrs)	Time spent interacting (min)
Wrist restraints	26±18.2	20±11.7	3.2±0.4	0±0	2.2±4.4
Exersides Refraint	28±8.4	11.2±10.0	4±0.7	2.6±1.6	66±73.8

^{*}Sedation-Agitation Scale; 1=comatose, 4=calm and cooperative, 7=dangerously agitated

Phase I Pilot Safety And Feasibility Study Of A Novel Restraint Device In Critically III Patients With Acute Respiratory Failure.

Biren B. Kamdar, MD, MBA, MHS, Janelle Fine, BS, Dale Needham, MD PhD, Renee Stapleton, MD PhD, Marie T. Pavini, MD, et al.

RESULTS

No safety events were reported. Feedback from patients, family and clinicians was positive and constructive.

	Day 1	l (n=7)	Day 2 (n=4)	
	Exersides	Traditional Restraint	Exersides	Traditional Restraint
Time in restraint (mean hours ± SD)	4.0±0.6	2.1±1.9	1.8±2.1	3.8±1.2
Wrist activity level, median (IQR) ^a	59 (16-177)	92 (24-213)	92 (28-213)	77 (22–206)
RASS sedation score (mean hours ± SD) ^b	-1.5±1.8	-0.5±1.8	-0.6±1.5	-1.7±1.2
CAM-ICU delirium (n)°	1	1	1	1
Satisfaction with Exersides (mean hours \pm SD) ^d	3.3	±0.7	3.8±0.4	

a) Represented as median (IQR) number of non-zero movements per 30-second epoch, as measured using bilateral wrist actigrpahy. Left and right wrist. b) Richmond Agitation-Sedation Scale (RASS). c) Confusion-Assessment Method (CAM-ICU). d) Quebec User Evaluation of Satisfaction with Assistive Technology (Quest 2.0) device subscale, higher score is better with a range from 1 (not satisfied at all) to 5 (very satisfied)